Targeting AR positive prostate cancer cells by the novel P300/CBP oral available PROTAC degrader

被引：0
|
作者：
Luo, Jie
Prolia, Abhijit
Qiao, Yuanyuan
Tian, Jean
Mannan, Rahul
Mahapatra, Somnath
Chen, Zhixiang
Seri, Rithvik
Wang, Shaomeng
Chinnaiyan, Arul
机构：
来源：
CANCER RESEARCH | 2023年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6048
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6048
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Role of histone deacetylase (HDAC1) and histone acetyltransferase (CBP/p300) in pathogenesis of prostate cancer
    Abbas, Ata
    Shukla, Sanjeev
    Umar, Saleem
    MacLennan, Gregory
    Gupta, Sanjay
    CANCER RESEARCH, 2009, 69
  • [42] A CRISPR Interference of CBP and p300 Selectively Induced Synthetic Lethality in Bladder Cancer Cells In Vitro
    Li, Jianfa
    Huang, ChenChen
    Xiong, Tiefu
    Zhuang, Changshui
    Zhuang, Chengle
    Li, Yawen
    Ye, Jing
    Gui, Yaoting
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (06): : 1276 - 1286
  • [43] Androgen deprivation increases p300 expression in prostate cancer cells.
    Heemers, Hannelore V.
    Sebo, Thomas J.
    Debes, Jose D.
    Raclaw, Kristin A.
    Murphy, Linda M.
    Hobisch, Alfred
    Culig, Zoran
    Tindall, Donald J.
    CANCER RESEARCH, 2006, 66 (08)
  • [44] P73γ transactivates the p21 promoter through preferential interaction with the p300/CBP-associated factor in human prostate cancer cells
    Momii, Yasutomo
    Izumi, Hiroto
    Shiota, Masaki
    Onitsuka, Takamitsu
    Abe, Tatsuya
    Kobayashi, Hidenori
    Miyamoto, Naoya
    Uchiumi, Takeshi
    Kohno, Kimitoshi
    ONCOLOGY REPORTS, 2007, 18 (02) : 411 - 416
  • [45] p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer
    Liu, Jinghui
    He, Daheng
    Cheng, Lijun
    Huang, Changkun
    Zhang, Yanquan
    Rao, Xiongjian
    Kong, Yifan
    Li, Chaohao
    Zhang, Zhuangzhuang
    Liu, Jinpeng
    Jones, Karrie
    Napier, Dana
    Lee, Eun Y.
    Wang, Chi
    Liu, Xiaoqi
    ONCOGENE, 2020, 39 (19) : 3939 - 3951
  • [46] Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses
    Yu, JX
    de Belle, I
    Liang, HG
    Adamson, ED
    MOLECULAR CELL, 2004, 15 (01) : 83 - 94
  • [47] p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer
    Jinghui Liu
    Daheng He
    Lijun Cheng
    Changkun Huang
    Yanquan Zhang
    Xiongjian Rao
    Yifan Kong
    Chaohao Li
    Zhuangzhuang Zhang
    Jinpeng Liu
    Karrie Jones
    Dana Napier
    Eun Y. Lee
    Chi Wang
    Xiaoqi Liu
    Oncogene, 2020, 39 : 3939 - 3951
  • [48] Oral small molecule modulators of p300/CBP to reprogram cancer cells and reactivate the p53 pathway in HPV-associated carcinomas.
    Kessler, Ulrich
    Cattori, Valentino
    Labelle, Marc
    Hentsch, Bernd
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer
    Yan, Yuqian
    Ma, Jian
    Wang, Dejie
    Lin, Dong
    Pang, Xiaodong
    Wang, Shangqian
    Zhao, Yu
    Shi, Lei
    Xue, Hui
    Pan, Yunqian
    Zhang, Jun
    Wahlestedt, Claes
    Giles, Francis J.
    Chen, Yu
    Gleave, Martin E.
    Collins, Collin C.
    Ye, Dingwei
    Wang, Yuzhuo
    Huang, Haojie
    EMBO MOLECULAR MEDICINE, 2019, 11 (11)
  • [50] p300/CBP-associated factor promotes autophagic degradation of δ-catenin through acetylation and decreases prostate cancer tumorigenicity
    Zhou, Rui
    Yang, Yi
    Park, So-Yeon
    Seo, Young-Woo
    Jung, Sang-Chul
    Kim, Kyung Keun
    Kim, Kwonseop
    Kim, Hangun
    SCIENTIFIC REPORTS, 2019, 9 (1)
12345